secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2025-10-24T23:59:59+00:00
Accession:  0001628280-25-046259
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas ARV-806 preclinical data: >90% KRAS G12D degradation for 7 days in xenograft models
--------------------------------------------------------------------------------

- ARV-806 degraded KRAS G12D with picomolar potency across pancreatic, colorectal, and lung cancer cell lines without affecting wild-type RAS.
- Compared with clinical-stage inhibitors and another G12D degrader, ARV-806 showed >25-fold greater antiproliferative potency and >40-fold higher degradation potency.
- Single dose degraded >90% of KRAS G12D for 7 days in colorectal xenograft, with c-MYC suppression and BIM induction for ≥5 days.
- Achieved ≥30% tumor volume reductions in pancreatic, colorectal CDX and lung PDX models at low doses.
- Phase 1 trial in KRAS G12D-mutated advanced solid tumors (NCT07023731) ongoing; orally bioavailable pan-KRAS degraders also identified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000162828025046259/0001628280-25-046259-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000162828025046259/arvn-20251024.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-046259

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer